 CHARLOTTESVILLE, Va., March 25, 2021 GLOBE NEWSWIRE -- Diffusion Pharmaceuticals Inc. NASDAQ: DFFN Diffusion or the Company, an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Companys Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate TSC, utilizing a transcutaneous oxygen monitoring TCOM device to evaluate the pharmacodynamic effects of TSC on peripheral tissue oxygenation. 